サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1435055

治療用血漿交換市場：技術、適応症、製品、エンドユーザー別-2023-2030年の世界予測

Therapeutic Plasma Exchange Market by Technology (Centrifugation, Membrane Separation), Indication (Hematologic Disorders, Metabolic Disorders, Neurological Disorders), Product, End-user - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 184 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
治療用血漿交換市場：技術、適応症、製品、エンドユーザー別-2023-2030年の世界予測
出版日: 2024年01月05日
発行: 360iResearch
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

治療用血漿交換市場規模は、2022年に7億1,047万米ドルと推定され、2023年には7億9,204万米ドルに達し、CAGR 10.02%で2030年には15億2,584万米ドルに達すると予測されています。

治療用血漿交換の世界市場

主な市場の統計
基準年[2022］ 7億1,047万米ドル
予測年【2023年 7億9,204万米ドル
予測年 [2030] 15億2,584万米ドル
CAGR（%） 10.02%
治療用血漿交換 Market-IMG1

治療用血漿交換は、血液中の有害物質を除去するために血液から血漿を除去・分離する医療処置であり、様々な自己免疫疾患や神経疾患の治療によく使われます。市場には、医療機器、代替輸液などの消耗品、サービスプロバイダー、病院、血液センター、およびこれらの治療を必要とする患者などのエンドユーザーが含まれます。治療用血漿交換は主に、ギラン・バレー症候群、重症筋無力症、血栓性血小板減少性紫斑病、多発性硬化症などの疾患の治療に応用されています。この市場のエンドユーザーは、病院、専門クリニック、外来患者施設に区分することができ、これらは治療用血漿交換療法の主要な提供者です。市場の成長は、自己免疫疾患の有病率の増加、ヘルスケアインフラの進歩、支持的なヘルスケア政策、血漿交換手技の有効性と安全性の向上などの要因に影響されます。アフェレシス技術の革新、必要とされる疾患の増加、医療投資の急増、有益な償還環境は、市場の主要な拡大動向です。しかし、TPE手技のコスト上昇、特定の層における認識不足、厳しい規制障壁、代替治療との競合といった課題は、市場拡大を妨げる可能性があります。しかし、ヘルスケア支出や教育の増加、治療精度を高めるためのITの統合は、市場にとって有利な機会です。成長を促進するために、この分野では、費用対効果の高いデバイス製造、治療最適化のための人工知能の応用、アフェレシス材料の品質向上、新しい治療用血漿交換アプリケーションの探求におけるブレークスルーが準備されており、技術革新と持続的な市場活力の未来を予告しています。

地域別の洞察

世界の治療用血漿交換（TPE）市場は、米国と欧州で成熟度が異なり、それぞれ米国食品医薬品局（FDA）と欧州医薬品庁（EMA）によって厳しく規制されているため、導入と技術革新が進んでいます。市場の関連性は、自己免疫疾患や重篤な疾患の罹患率の上昇と、保険適用やヘルスケア・インフラなどの要因に影響される投資や消費者の需要の増加によって強化されています。先進国はTPEを改善するための技術的進歩に重点を置き、安全性と効率に対する消費者の高い期待に応えようとしています。しかし、このような成長軌道は、コスト管理、規制遵守、専門的訓練を受けた人材の必要性といった課題とのバランスを保っています。さらに、EUレベルでは、国境を越えた数多くの取り組みや、ヘルスケア分野のイノベーションを支援するホライゾン・欧州・プログラムが提供するような資金提供の機会もあり、調査は非常に協力的です。

アジア、アフリカ、南北アメリカの一部などの新興市場は、医療投資の増加や規制のハードルの低さから大きな可能性を秘めており、未開拓の患者層が膨大に存在することを示しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは治療用血漿交換市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、治療用血漿交換市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-治療用血漿交換市場の市場規模および予測は？

2-治療用血漿交換市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-治療用血漿交換市場における技術動向と規制の枠組みは？

4-治療用血漿交換市場における主要ベンダーの市場シェアは？

5-治療用血漿交換市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 自己免疫疾患や心臓病の有病率の増加による治療用血漿交換の必要性
      • アフェレーシス技術の進歩
    • 抑制要因
      • デバイスと治療用血漿交換プロシージャに関連するコスト
    • 機会
      • 治療用血漿交換テクノロジーの進歩と神経筋疾患における免疫調節効果
      • 小児集中治療における治療用血漿交換（TPE）の需要急増
    • 課題
      • TPEにおけるアフェレーシス手順に関連する合併症
  • 市場セグメンテーション分析
    • 技術：膜分離は、治療用血漿交換の場合に優先的に選択される
    • 適応症：生命を脅かす血液疾患に対する治療用血漿交換の広範な使用
    • 製品：消耗品の技術進歩のニーズは、血漿交換装置およびシステムと互換性がある必要がある
    • エンドユーザー：採血センターと血液成分プロバイダーは、より大きなユーザーベースと大規模な手術治療のサポートを指揮
  • 市場動向分析
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 治療用血漿交換市場：技術別

  • 遠心分離
  • 膜分離

第7章 治療用血漿交換市場：適応症別

  • 血液疾患
    • 非定型溶血性尿毒症症候群
    • 過粘稠度症候群
    • 重度/症候性クリオグロブリン血症
    • 血栓性血小板減少性紫斑病
  • 代謝障害
  • 神経学的障害
    • 慢性炎症性脱髄性多発神経障害
    • ギランバレー症候群
    • 多発性硬化症
    • 重症筋無力症
    • PANDAS
  • 腎疾患
    • 抗体媒介腎移植拒絶反応
    • グッドパスチャー症候群
    • ウェゲナー肉芽腫症

第8章 治療用血漿交換市場：製品別

  • 消耗品
  • デバイス

第9章 治療用血漿交換市場：エンドユーザー別

  • 採血センターと血液成分提供者
  • 病院と輸血センター

第10章 南北アメリカの治療用血漿交換市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の治療用血漿交換市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの治療用血漿交換市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析
    • 契約、コラボレーション、パートナーシップ
    • 新製品発売と機能強化

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Asahi Kasei Medical Co., Ltd.
    • B. Braun Melsungen AG
    • Baxter International Inc.
    • Bio Products Laboratory Ltd.
    • Cerus Corporation
    • Charles River Laboratories International, Inc.
    • CSL Behring
    • Elastrin Therapeutics, Inc.
    • Fresenius Medical Care AG & Co. KGaA
    • Grifols, S.A.
    • Haemonetics Corporation
    • Infomed SA
    • Kaneka Corporation
    • Kedrion Biopharma Inc.
    • Mallinckrodt PLC
    • Medica S.P.A.
    • Medicap Clinic GmbH
    • MEISE Medizintechnik GmbH
    • Miltenyi Biotec
    • Nikkiso Co., Ltd.
    • Pall Corporation
    • Plasma Technologies, LLC
    • Qingdao Haier Biomedical Co., Ltd
    • Sb-Kawasumi Laboratories, Inc.
    • Terumo BCT, Inc.
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. THERAPEUTIC PLASMA EXCHANGE MARKET RESEARCH PROCESS
  • FIGURE 2. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, 2022 VS 2030
  • FIGURE 3. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 5. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 6. THERAPEUTIC PLASMA EXCHANGE MARKET DYNAMICS
  • FIGURE 7. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
  • FIGURE 8. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
  • FIGURE 10. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
  • FIGURE 12. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 14. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 16. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY STATE, 2022 VS 2030 (%)
  • FIGURE 18. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 23. THERAPEUTIC PLASMA EXCHANGE MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 24. THERAPEUTIC PLASMA EXCHANGE MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. THERAPEUTIC PLASMA EXCHANGE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 6. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY MEMBRANE SEPARATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 9. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 11. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HYPERVISCOSITY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY SEVERE/SYMPTOMATIC CRYOGLOBULINEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY THROMBOTIC THROMBOCYTOPENIC PURPURA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 18. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY GUILLAIN-BARRE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY MYASTHENIA GRAVIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PANDAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 25. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY ANTIBODY-MEDIATED RENAL TRANSPLANT REJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY GOODPASTURE SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY WEGENER'S GRANULOMATOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY BLOOD COLLECTION CENTERS & BLOOD COMPONENT PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HOSPITALS & TRANSFUSION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 178. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 290. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 297. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 298. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 305. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 311. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 312. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY HEMATOLOGIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY RENAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES THERAPEUTIC PLASMA EXCHANGE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)

TABLE 317

目次
Product Code: MRR-BC0B37A58A48

[184 Pages Report] The Therapeutic Plasma Exchange Market size was estimated at USD 710.47 million in 2022 and expected to reach USD 792.04 million in 2023, at a CAGR 10.02% to reach USD 1,525.84 million by 2030.

Global Therapeutic Plasma Exchange Market

KEY MARKET STATISTICS
Base Year [2022] USD 710.47 million
Estimated Year [2023] USD 792.04 million
Forecast Year [2030] USD 1,525.84 million
CAGR (%) 10.02%
Therapeutic Plasma Exchange Market - IMG1

Therapeutic plasma exchange is a medical procedure that involves removing and separating plasma from the blood to remove harmful substances from the bloodstream, often used to treat a variety of autoimmune and neurological disorders. The market includes medical devices, consumables such as replacement fluids, service providers, hospitals, blood centers, and end-users such as patients requiring these treatments. Therapeutic plasma exchange is primarily applied in the treatment of conditions such as Guillain-Barre syndrome, myasthenia gravis, thrombotic thrombocytopenic purpura, and multiple sclerosis, among others. End-users of this market can be segmented into hospitals, specialized clinics, and outpatient facilities, which are the primary providers of therapeutic plasma exchange therapy. Growth in the market is influenced by factors such as the increasing prevalence of autoimmune diseases, advancements in healthcare infrastructure, supportive healthcare policies, and the increased effectiveness and safety of plasma exchange procedures. Innovations in apheresis technology and the climbing cases of diseases required, paired with the surge in healthcare investments and beneficial reimbursement climates are market major market upscaling trends. However, challenges such as the elevated cost of TPE procedures, lack of awareness in certain demographics, strict regulatory barriers, and competition from alternative treatments may hinder market progression. However, increased healthcare expenditure and education, and the integration of IT to refine treatment accuracy are lucrative opportunities in the market. To foster growth, the sector is poised for breakthroughs in cost-effective device manufacturing, the application of artificial intelligence for treatment optimization, enhanced apheresis material quality, and exploration of new therapeutic plasma exchange applications, heralding a future of innovation and sustained market vitality.

Regional Insights

The global therapeutic plasma exchange (TPE) market showcases variable maturity in the United States and Europe leading in adoption and innovation, regulated strictly by the FDA and EMA respectively. Market relevance is bolstered by the escalating incidence of autoimmune diseases and critical ailments, matched with increasing investments and consumer demand influenced by factors such as insurance coverage and healthcare infrastructure. Developed nations focus on technological advancements to ameliorate TPE, striving to meet high consumer expectations for safety and efficiency. This growth trajectory, however, is balanced by the challenges of cost management, regulatory compliance, and the necessity for professionally trained personnel. Additionally, research is highly collaborative at the EU level, with numerous cross-border initiatives and funding opportunities, such as those provided by the Horizon Europe program, which supports innovation in the healthcare sector.

Emerging markets such as those in Asia, Africa, and parts of the Americas present significant potential due to rising healthcare investments and less stringent regulatory hurdles, indicating a vast untapped patient demographic.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Therapeutic Plasma Exchange Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Therapeutic Plasma Exchange Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Plasma Exchange Market, highlighting leading vendors and their innovative profiles. These include Asahi Kasei Medical Co., Ltd., B. Braun Melsungen AG, Baxter International Inc., Bio Products Laboratory Ltd., Cerus Corporation, Charles River Laboratories International, Inc., CSL Behring, Elastrin Therapeutics, Inc., Fresenius Medical Care AG & Co. KGaA, Grifols, S.A., Haemonetics Corporation, Infomed SA, Kaneka Corporation, Kedrion Biopharma Inc., Mallinckrodt PLC, Medica S.P.A., Medicap Clinic GmbH, MEISE Medizintechnik GmbH, Miltenyi Biotec, Nikkiso Co., Ltd., Pall Corporation, Plasma Technologies, LLC, Qingdao Haier Biomedical Co., Ltd, Sb-Kawasumi Laboratories, Inc., and Terumo BCT, Inc..

Market Segmentation & Coverage

This research report categorizes the Therapeutic Plasma Exchange Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Centrifugation
    • Membrane Separation
  • Indication
    • Hematologic Disorders
      • Atypical Hemolytic Uremic Syndrome
      • Hyperviscosity Syndrome
      • Severe/Symptomatic Cryoglobulinemia
      • Thrombotic Thrombocytopenic Purpura
    • Metabolic Disorders
    • Neurological Disorders
      • Chronic Inflammatory Demyelinating Polyneuropathy
      • Guillain-Barre Syndrome
      • Multiple Sclerosis
      • Myasthenia Gravis
      • PANDAS
    • Renal Disorders
      • Antibody-mediated Renal Transplant Rejection
      • Goodpasture Syndrome
      • Wegener's Granulomatosis
  • Product
    • Consumables
    • Devices
  • End-user
    • Blood Collection Centers & Blood Component Providers
    • Hospitals & Transfusion Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Therapeutic Plasma Exchange Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Therapeutic Plasma Exchange Market?

3. What are the technology trends and regulatory frameworks in the Therapeutic Plasma Exchange Market?

4. What is the market share of the leading vendors in the Therapeutic Plasma Exchange Market?

5. Which modes and strategic moves are suitable for entering the Therapeutic Plasma Exchange Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Therapeutic Plasma Exchange Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need of Therapeutic Plasma Exchange due to Rise in Prevalence of Autoimmune and Cardiac Diseases
      • 5.1.1.2. Technical Advancement in Apheresis Technologies
    • 5.1.2. Restraints
      • 5.1.2.1. Cost Associated with the Devices and Therapeutic Plasma Exchange Procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in Therapeutic Plasma Exchange Technology and its Immunomodulatory Effect in Neuromuscular Diseases
      • 5.1.3.2. Surge in Demand for Therapeutic Plasma Exchange (TPE) in Pediatric Intensive Care
    • 5.1.4. Challenges
      • 5.1.4.1. Complications Associated with the Apheresis Procedure in TPE
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Membrane separation are preferred selection while therapeutic plasma exchange
    • 5.2.2. Indication: Extensive usage of therapeutic plasma exchange for life threatening hematologic disorders
    • 5.2.3. Product: Technological advancement in consumables needs should to be compatible with their plasma exchange devices and systems
    • 5.2.4. End-user: Blood collection centers & blood component providers are commanding larger user base and support for large scale operative treatments
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of COVID-19
  • 5.5. Cumulative Impact of Russia-Ukraine Conflict
  • 5.6. Cumulative Impact of High Inflation
  • 5.7. Porter's Five Forces Analysis
    • 5.7.1. Threat of New Entrants
    • 5.7.2. Threat of Substitutes
    • 5.7.3. Bargaining Power of Customers
    • 5.7.4. Bargaining Power of Suppliers
    • 5.7.5. Industry Rivalry
  • 5.8. Value Chain & Critical Path Analysis
  • 5.9. Regulatory Framework
  • 5.10. Client Customization

6. Therapeutic Plasma Exchange Market, by Technology

  • 6.1. Introduction
  • 6.2. Centrifugation
  • 6.3. Membrane Separation

7. Therapeutic Plasma Exchange Market, by Indication

  • 7.1. Introduction
  • 7.2. Hematologic Disorders
    • 7.3.1. Atypical Hemolytic Uremic Syndrome
    • 7.3.2. Hyperviscosity Syndrome
    • 7.3.3. Severe/Symptomatic Cryoglobulinemia
    • 7.3.4. Thrombotic Thrombocytopenic Purpura
  • 7.3. Metabolic Disorders
  • 7.4. Neurological Disorders
    • 7.5.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 7.5.2. Guillain-Barre Syndrome
    • 7.5.3. Multiple Sclerosis
    • 7.5.4. Myasthenia Gravis
    • 7.5.5. PANDAS
  • 7.5. Renal Disorders
    • 7.6.1. Antibody-mediated Renal Transplant Rejection
    • 7.6.2. Goodpasture Syndrome
    • 7.6.3. Wegener's Granulomatosis

8. Therapeutic Plasma Exchange Market, by Product

  • 8.1. Introduction
  • 8.2. Consumables
  • 8.3. Devices

9. Therapeutic Plasma Exchange Market, by End-user

  • 9.1. Introduction
  • 9.2. Blood Collection Centers & Blood Component Providers
  • 9.3. Hospitals & Transfusion Centers

10. Americas Therapeutic Plasma Exchange Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Therapeutic Plasma Exchange Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Plasma Exchange Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player
    • 13.3.1. Agreement, Collaboration, & Partnership
      • 13.3.1.1. HealthyLongevity.clinic recently partnered with Dr. Dobri Kiprov
    • 13.3.2. New Product Launch & Enhancement
      • 13.3.2.1. Dr. Savage Introduces Plasma Exchange for 2024 Weight Loss
      • 13.3.2.2. MaxWell Clinic offers Therapeutic Plasma Exchange (TPE) as a Treatment Option for Dementia, Alzheimer's, Memory Los, and Autoimmune Disease

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Asahi Kasei Medical Co., Ltd.
    • 14.1.2. B. Braun Melsungen AG
    • 14.1.3. Baxter International Inc.
    • 14.1.4. Bio Products Laboratory Ltd.
    • 14.1.5. Cerus Corporation
    • 14.1.6. Charles River Laboratories International, Inc.
    • 14.1.7. CSL Behring
    • 14.1.8. Elastrin Therapeutics, Inc.
    • 14.1.9. Fresenius Medical Care AG & Co. KGaA
    • 14.1.10. Grifols, S.A.
    • 14.1.11. Haemonetics Corporation
    • 14.1.12. Infomed SA
    • 14.1.13. Kaneka Corporation
    • 14.1.14. Kedrion Biopharma Inc.
    • 14.1.15. Mallinckrodt PLC
    • 14.1.16. Medica S.P.A.
    • 14.1.17. Medicap Clinic GmbH
    • 14.1.18. MEISE Medizintechnik GmbH
    • 14.1.19. Miltenyi Biotec
    • 14.1.20. Nikkiso Co., Ltd.
    • 14.1.21. Pall Corporation
    • 14.1.22. Plasma Technologies, LLC
    • 14.1.23. Qingdao Haier Biomedical Co., Ltd
    • 14.1.24. Sb-Kawasumi Laboratories, Inc.
    • 14.1.25. Terumo BCT, Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing